Skip Nav Destination
Issue Highlights
- Mass cytometry of evolving aplastic anemia
- Combined PET and ctDNA response predictors in FL
- Grading thrombocytopenia after CAR-T therapy
- ATF6 activation, BCL-xL, and type 2 CALR-mutant MPNs
- CME article: AlloHCT for Hodgkin lymphoma after checkpoint inhibition
- Perspective: current challenges with GVHD and GVL
- The TFH/TFR pathway in FVIII immune responses
Latest in Blood
Combined PET and ctDNA response as a predictor of POD24 for follicular lymphoma after first-line induction treatment
Available to Purchase
Alexis Claudel; Anne-Ségolène Cottereau; Emmanuel Bachy; Emmanuel Itti; Pierre Feugier; Cedric Rossi; Francois Lemonnier; Vincent Camus; Nicolas Daguindau; Guillaume Cartron; Emmanuelle Nicolas-Virelizier; Diana-Laure Mboumba; Christophe Cardoso; Côme Bommier; Benoit Tessoulin; Christophe Fruchart; Adrien Gilbert; Eric Durot; Emmanuel Fleck; Gian Matteo Pica; Hacene Zerazhi; Stephanie Guidez; Morgane Cheminant; Clementine Sarkozy; Luc Xerri; Laetitia Vercellino; Nesrine Trabelsi; Lucie Gomes; Cedric Portugues; Pierre-Julien Viailly; Marie-Hélène Delfau-Larue; Franck Morschhauser
Remestemcel-L-rknd (Ryoncil): the first approved cellular therapy for steroid-refractory acute GVHD
Available to Purchase
Aaron M. Etra; James L.M. Ferrara; John E Levine
Aziz Nazha; Olivier Elemento; Sanjay Ahuja; Barbara D Lam; Moses Miles; Roni Shouval; Shannon K. McWeeney; Shireen Sirhan; Andrew Srisuwananukorn; Torsten Haferlach
Advertisement intended for health care professionals